ELOXX PHARMACEUTICALS, INC.: 10-Q filed 2012-11-14

Name: ELOXX PHARMACEUTICALS, INC.: 10-Q filed 2012-11-14
Creator: ELOXX PHARMACEUTICALS, INC.

What ELOXX PHARMACEUTICALS, INC. reported in its quarterly report filed 2012-11-14 (fiscal Q1 2013): 26 published measures, 62 facts as tagged in accession 0001144204-12-062352.

This filing

Form: 10-Q (quarterly report)
Filed: 2012-11-14
Fiscal period: fiscal Q1 2013
Accession: 0001144204-12-062352 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All ELOXX PHARMACEUTICALS, INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

Period	Value	Unit	Days
At 2012-09-30	6,260,145	USD
At 2012-06-30	6,954,869	USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

Period	Value	Unit	Days
At 2012-09-30	3,630,728	USD
At 2012-06-30	3,501,841	USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

Period	Value	Unit	Days
At 2012-09-30	2,629,417	USD
At 2012-06-30	3,453,028	USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

Period	Value	Unit
At 2012-09-30	1,312,056	USD
At 2012-06-30	2,001,325	USD
At 2011-09-30	2,841,974	USD
At 2011-06-30	3,609,954	USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

Period	Value	Unit	Days
2012-07-01 to 2012-09-30	-2,085,454	USD	92
1998-07-01 to 2012-09-30	-59,022,208	USD	5206
2011-07-01 to 2011-09-30	-1,038,983	USD	92

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

Period	Value	Unit	Days
2012-07-01 to 2012-09-30	-636,454	USD	92
1998-07-01 to 2012-09-30	-37,658,844	USD	5206
2011-07-01 to 2011-09-30	-1,090,238	USD	92

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

Period	Value	Unit	Days
2012-07-01 to 2012-09-30	1,281	USD	92
1998-07-01 to 2012-09-30	185,947	USD	5206

Revenue

Revenue under this specific accounting concept. A missing value is not zero; filers can use other revenue concepts.

Period	Value	Unit	Days
1998-07-01 to 2012-09-30	1,790,000	USD	5206

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

Period	Value	Unit	Days
2012-07-01 to 2012-09-30	94,183	USD	92
1998-07-01 to 2012-09-30	45,527,276	USD	5206
2011-07-01 to 2011-09-30	451,097	USD	92

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

Period	Value	Unit	Days
2012-07-01 to 2012-09-30	-146,998	USD	92
1998-07-01 to 2012-09-30	-6,556,376	USD	5206
2011-07-01 to 2011-09-30	-128,839	USD	92

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

Period	Value	Unit	Days
At 2012-09-30	6,491	USD
At 2012-06-30	5,857	USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

Period	Value	Unit	Days
2012-07-01 to 2012-09-30	153,562	USD	92
1998-07-01 to 2012-09-30	12,259,515	USD	5206
2011-07-01 to 2011-09-30	123,551	USD	92

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

Period	Value	Unit	Days
2012-07-01 to 2012-09-30	-1,246,153	USD	92
1998-07-01 to 2012-09-30	-52,306,435	USD	5206
2011-07-01 to 2011-09-30	-1,280,145	USD	92

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

Period	Value	Unit	Days
At 2012-09-30	2,771,699	USD
At 2012-06-30	3,549,849	USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

Period	Value	Unit	Days
At 2012-09-30	3,436,261	USD
At 2012-06-30	3,163,317	USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

Period	Value	Unit	Days
At 2012-09-30	932,167	USD
At 2012-06-30	594,514	USD

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

Period	Value	Unit	Days
2012-07-01 to 2012-09-30	513,433	USD	92
1998-07-01 to 2012-09-30	21,749,038	USD	5206
2011-07-01 to 2011-09-30	634,186	USD	92

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

Period	Value	Unit	Days
At 2012-09-30	116,753,185	shares
At 2012-06-30	94,112,483	shares

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

Period	Value	Unit	Days
At 2012-09-30	71,611,793	USD
At 2012-06-30	69,952,152	USD

Net intangible assets excluding goodwill

Intangible assets other than goodwill after amortization and impairment. Internally developed intangibles are usually not recognized, so this understates what a company relies on.

Period	Value	Unit	Days
At 2012-09-30	3,476,784	USD
At 2012-06-30	3,393,992	USD

Other noncurrent liabilities

Noncurrent liabilities the filer does not present separately. The composition differs by filer and is described only in the filing.

Period	Value	Unit	Days
At 2012-09-30	99,728	USD
At 2012-06-30	99,728	USD

Accrued current liabilities

Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.

Period	Value	Unit	Days
At 2012-09-30	304,986	USD
At 2012-06-30	369,695	USD

Net income available to common stockholders

Net income after preferred dividends and similar adjustments, the numerator for basic earnings per share. It can be lower than reported net income.

Period	Value	Unit	Days
2012-07-01 to 2012-09-30	-2,709,623	USD	92
1998-07-01 to 2012-09-30	-70,149,918	USD	5206
2011-07-01 to 2011-09-30	-1,947,829	USD	92

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

Period	Value	Unit	Days
2012-07-01 to 2012-09-30	732,720	USD	92
1998-07-01 to 2012-09-30	32,347,397	USD	5206
2011-07-01 to 2011-09-30	645,959	USD	92

Other nonoperating income or expense

Other income or expense outside operations under this concept. The composition is filer-specific and can include one-time items.

Period	Value	Unit	Days
1998-07-01 to 2012-09-30	205,390	USD	5206

Change in accounts payable

The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.

Period	Value	Unit	Days
2012-07-01 to 2012-09-30	337,653	USD	92
1998-07-01 to 2012-09-30	932,167	USD	5206
2011-07-01 to 2011-09-30	389,565	USD	92

Inspect the source

Entity: ELOXX PHARMACEUTICALS, INC. / CIK 0001035354
Captured: 2026-09-20T05:15:09.498Z
SEC response SHA-256: b351a9ed06ee3e6f1d738bbdb3852b866526fe561e11a7ffd4a81bc43bb27195

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python

import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001035354.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))